How well do ACPA discriminate and predict RA in the general population: A study based on 12 590 population-representative Swedish twins

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 119-125

  Hensvold, Aase Haj ^a,b   Frisell, Thomas ^a   Magnusson, Patrik K E ^b   Holmdahl, Rikard ^a   Askling, Johan ^a,b   Catrina, Anca Irinel ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; BLOOD DONOR; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE REGISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREDICTION; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWEDE (PEOPLE); ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SWEDEN; TWINS;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; SWEDEN;

EID: 84966289956     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208980     Document Type: Article

References (51)

1. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012;71:638-41.
2. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
3. Rantapää-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
4. van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011;70:128-33.
5. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum 2013;65:899-910.
6. Chibnik LB, Mandl LA, Costenbader KH, et al. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009;36:706-11.
7. Koivula MK, Heliövaara M, Ramberg J, et al. Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis. Ann Rheum Dis 2007;66:1450-5.
8. Demoruelle MK, Parish MC, Derber LA, et al. Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum 2013;65:2243-52.
9. Jørgensen KT, Wiik A, Pedersen M, et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann Rheum Dis 2008;67:860-6.
10. Arkema EV, Goldstein BL, Robinson W, et al. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study. Arthritis Res Ther 2013;15:R159.
11. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7: e35296.
12. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis2013;72:652-8.
13. Hensvold AH, Joshua V, Li W, et al. Serum RANKL levels associate with anticitrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther 2015;17:239.
14. Kastbom A, Forslind K, Ernestam S, et al. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 2016;75:356-61.
15. El-Gabalawy HS, Robinson DB, Hart D, et al. Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol 2009;36:1130-5.
16. Ärlestig L, Mullazehi M, Kokkonen H, et al. Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden. Ann Rheum Dis 2012;71:825-9.
17. Barra L, Scinocca M, Saunders S, et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum 2013;65:1439-47.
18. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
19. Hensvold AH, Magnusson PK, Joshua V, et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2015;74:375-80.
20. Magnusson PK, Almqvist C, Rahman I, et al. The Swedish twin registry: establishment of a biobank and other recent developments. Twin Res Hum Genet 2013;16:317-29.
21. Rahman I, Bennet AM, Pedersen NL, et al. Genetic dominance influences blood biomarker levels in a sample of 12, 000 Swedish elderly twins. Twin Res Hum Genet 2009;12:286-94.
22. Lichtenstein P, Sullivan PF, Cnattingius S, et al. The Swedish Twin Registry in the third millennium: an update. Twin Res Hum Genet 2006;9:875-82.
23. Lichtenstein P, De Faire U, Floderus B, et al. The Swedish Twin Registry: a unique resource for clinical, epidemiological and genetic studies. J Intern Med 2002;252:184-205.
24. Jiang X, Kallberg H, Chen Z, et al. An Immunochip-based interaction study ofcontrasting interaction effects with smoking in ACPA-positive versus ACPA-negative rheumatoid arthritis. Rheumatology (Oxford) 2016;55:149-55.
25. Sadr-Azodi O, Andrén-Sandberg Å, Orsini N, et al. Cigarette smoking, smoking cessation and acute pancreatitis: a prospective population-based study. Gut 2012;61:262-7.
26. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
27. van Venrooij WJ, Zendman AJ. Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis. Clin Rev Allergy Immunol 2008;34:36-9.
28. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
29. Wegner N, Lundberg K, Kinloch A, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 2010;233:34-54.
30. Hermansson M, Artemenko K, Ossipova E, et al. MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl 2010;4:511-18.
31. Hansson M, Mathsson L, Schlederer T, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther 2012;14:R201.
32. Burkhardt H, Sehnert B, Bockermann R, et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005;35:1643-52.
33. Eriksson UK, Pedersen NL, Reynolds CA, et al. Associations of gene sequence variation and serum levels of C-reactive protein and interleukin-6 with Alzheimer's disease and dementia. J Alzheimers Dis 2011;23:361-9.
34. Dilthey AT, Moutsianas L, Leslie S, et al. HLA. IMP-an integrated framework for imputing classical HLA alleles from SNP genotypes. Bioinformatics 2011;27:968-72.
35. Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012;44:291-6.
36. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
37. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
38. Knight A, Sandin S, Askling J. Occupational risk factors for Wegener's granulomatosis: a case-control study. Ann Rheum Dis 2010;69:737-40.
39. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 2003;138:40-4.
40. Bossuyt X, Coenen D, Fieuws S, et al. Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor. Ann Rheum Dis 2009;68:287-9.
41. Silveira IG, Burlingame RW, von Mühlen CA, et al. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007;26:1883-9.
42. Zintzaras E, Papathanasiou AA, Ziogas DC, et al. The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates. BMC Musculoskelet Disord 2012;13:113.
43. Neovius M, Simard JF, Askling J. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011;70:624-9.
44. Eriksson JK, Neovius M, Ernestam S, et al. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken) 2013;65:870-8.
45. Pietrapertosa D, Tolusso B, Gremese E, et al. Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of likelihood ratios. Clin Chem Lab Med 2010;48:829-34.
46. Terao C, Ohmura K, Ikari K, et al. Effects of smoking and shared epitope on the production of anti-citrullinated peptide antibody in a Japanese adult population. Arthritis Care Res (Hoboken) 2014;66:1818-27.
47. Brouwer EAS, Bootsma H, Roozendaal C, et al. Presence of ACPA in a Large (>40.000) Population Based Cohort from the Netherlands [abstract]. Arthritis Rheumatol 2015;74:85.
48. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008;58:3009-19.
49. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
50. Fernandes-Cerqueira C, Ossipova E, Gunasekera S, et al. Targeting of anti-citrullinated protein/peptide antibodies in rheumatoid arthritis using peptides mimicking endogenously citrullinated fibrinogen antigens. Arthritis Res Ther 2015;17:155.
51. Sebbag M, Moinard N, Auger I, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006;36:2250-63.